ATE267015T1 - Verbindungen und verfahren zur behandlung von krebs - Google Patents

Verbindungen und verfahren zur behandlung von krebs

Info

Publication number
ATE267015T1
ATE267015T1 AT95933071T AT95933071T ATE267015T1 AT E267015 T1 ATE267015 T1 AT E267015T1 AT 95933071 T AT95933071 T AT 95933071T AT 95933071 T AT95933071 T AT 95933071T AT E267015 T1 ATE267015 T1 AT E267015T1
Authority
AT
Austria
Prior art keywords
compounds
methods
treating cancer
cancer
treating
Prior art date
Application number
AT95933071T
Other languages
English (en)
Inventor
Chung K Chu
Yung-Chi Cheng
Original Assignee
Univ Georgia Res Found
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,298 external-priority patent/US5817667A/en
Application filed by Univ Georgia Res Found, Univ Yale filed Critical Univ Georgia Res Found
Application granted granted Critical
Publication of ATE267015T1 publication Critical patent/ATE267015T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT95933071T 1994-09-06 1995-09-05 Verbindungen und verfahren zur behandlung von krebs ATE267015T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/301,298 US5817667A (en) 1991-04-17 1994-09-06 Compounds and methods for the treatment of cancer
US39063395A 1995-02-17 1995-02-17
PCT/US1995/011464 WO1996007413A1 (en) 1994-09-06 1995-09-05 Compounds and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE267015T1 true ATE267015T1 (de) 2004-06-15

Family

ID=26972285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95933071T ATE267015T1 (de) 1994-09-06 1995-09-05 Verbindungen und verfahren zur behandlung von krebs

Country Status (31)

Country Link
US (3) US6063787A (de)
EP (2) EP1468687A1 (de)
JP (1) JP3979662B2 (de)
KR (1) KR100374477B1 (de)
CN (3) CN1827108A (de)
AP (1) AP783A (de)
AT (1) ATE267015T1 (de)
AU (1) AU704977B2 (de)
BG (1) BG63122B1 (de)
BR (1) BR9508886A (de)
CA (1) CA2199117C (de)
CZ (1) CZ297873B6 (de)
DE (1) DE69533066T2 (de)
DK (1) DK0781136T3 (de)
ES (1) ES2219666T3 (de)
FI (1) FI970918L (de)
HU (1) HUT77172A (de)
IL (1) IL115156A (de)
IS (1) IS2011B (de)
MY (1) MY121548A (de)
NO (1) NO313268B1 (de)
NZ (1) NZ335013A (de)
OA (1) OA10473A (de)
PL (2) PL188359B1 (de)
PT (1) PT781136E (de)
RO (1) RO118748B1 (de)
RU (1) RU2168995C2 (de)
SI (1) SI0781136T1 (de)
SK (1) SK284564B6 (de)
WO (1) WO1996007413A1 (de)
ZA (1) ZA957483B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
ATE413881T1 (de) 1997-08-08 2008-11-15 Celmed Oncology Usa Inc Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
ES2172303T3 (es) 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
EA200700564A1 (ru) 1998-02-25 2007-08-31 Эмори Юниверсити 2`-фторнуклеозиды
AU2004201676B2 (en) * 1999-03-29 2006-03-09 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
DE60042921D1 (de) * 1999-03-29 2009-10-22 Shire Canada Inc Verwendung von cytidinderivaten zur behandlung von leukämie
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
WO2001022950A2 (en) 1999-09-24 2001-04-05 Shire Biochem Inc. Diosolane nucleoside analogs for the treatment or prevention of viral infection
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1600452A3 (de) 1999-11-12 2008-09-10 Pharmasset, Inc. Herstellung von 2'-Deoxy-L-Nukleoside
CN100376570C (zh) * 2000-10-13 2008-03-26 希拉生物化学股份有限公司 改善胞间传输的二氧戊环类似物
WO2002056832A2 (en) 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
ATE450265T1 (de) * 2001-03-23 2009-12-15 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
CN1744902B (zh) * 2001-03-23 2010-05-26 希拉加拿大股份有限公司 治疗癌症的药物组合
AU2002242561A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
CA2465682A1 (en) * 2001-11-02 2003-05-08 Shire Biochem Inc. Methods of treating leukemia
EP2055300B1 (de) * 2001-11-19 2016-01-27 Medigene AG Arzneimittel enthaltend Isopropylmyristat und ein Catechin
CN1556988B (zh) 2002-06-21 2011-09-14 Lg电子株式会社 具有用于管理记录在其上面的视频数据的再现的数据结构的记录介质
CA2465105C (en) 2002-06-21 2012-08-28 Lg Electronics Inc. Recording medium having data structure for managing reproduction of video data recorded thereon
WO2004001750A1 (en) 2002-06-24 2003-12-31 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
KR20040000290A (ko) 2002-06-24 2004-01-03 엘지전자 주식회사 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법
EP1518240B1 (de) 2002-06-28 2014-05-07 LG Electronics, Inc. Aufzeichnungsmedium mit einer datenstruktur zur verwaltung der aufzeichnung und wiedergabe von darauf aufgezeichneten mehrwegedaten und aufzeichnungs- und wiedergabeverfahren und -vorrichtungen
CN100372535C (zh) * 2002-09-24 2008-03-05 诺瓦提斯公司 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途
EP1552519A4 (de) 2002-10-14 2006-08-16 Lg Electronics Inc Aufzeichnungsmedium mit einer datenstruktur zur verwaltung der wiedergabe mehrerer darauf aufgezeichneter audioströme und aufzeichnungs- und wiedergabeverfahren und vorrichtungen
WO2004036578A1 (en) 2002-10-15 2004-04-29 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple graphics streams recorded thereon and recording and reproducing methods and apparatuses
RU2313139C2 (ru) 2002-11-12 2007-12-20 Эл Джи Электроникс Инк. Носитель записи со структурой данных для управления воспроизведением записанных на нем видеоданных нескольких каналов воспроизведения и способы и устройства записи и воспроизведения
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
US7606463B2 (en) 2003-02-24 2009-10-20 Lg Electronics, Inc. Recording medium having data structure for managing playback control and recording and reproducing methods and apparatuses
US7693394B2 (en) 2003-02-26 2010-04-06 Lg Electronics Inc. Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses
US7809775B2 (en) 2003-02-27 2010-10-05 Lg Electronics, Inc. Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses
CN100397882C (zh) 2003-02-28 2008-06-25 Lg电子株式会社 具有用于管理记录其上的视频数据的随机/洗牌重现的数据结构的记录媒体以及记录和重现的方法和装置
US7620301B2 (en) 2003-04-04 2009-11-17 Lg Electronics Inc. System and method for resuming playback
WO2005037300A1 (en) 2003-10-09 2005-04-28 Medigene Ag The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
BRPI0613796A2 (pt) * 2005-06-07 2011-02-15 Univ Yale composicões farmacêuticas e seus usos, e métodos de tratamento de cáncer e outras condições ou estados patológicos, por meio do uso de clevudina (lfmau) e telbivudina (ldt)
CN101511375B (zh) * 2005-12-02 2012-09-05 耶鲁大学 L-胞嘧啶核苷类似物在制备用于治疗癌症和其它病症或疾病状态的药物中的应用
NO324263B1 (no) * 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
WO2008030373A2 (en) * 2006-09-01 2008-03-13 University Of Georgia Research Foundation, Inc. L- oddc prodrugs for cancer
RU2322243C1 (ru) * 2006-10-20 2008-04-20 Наталья Юрьевна Костюкова Фармацевтическая композиция для лечения поражений роговицы
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
CA3045228C (en) * 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
PT82580B (pt) * 1985-05-15 1989-01-17 Wellcome Found Processo para a preparacao de 2',3'- didesoxinucleosidos e de composicoes farmaceuticas que os contem
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
DK167377B1 (da) * 1985-09-17 1993-10-25 Wellcome Found 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
IN164556B (de) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
FR2601385B1 (fr) * 1986-07-09 1989-09-29 Sucre Rech & Dev Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
ATE108183T1 (de) * 1987-03-24 1994-07-15 Nycomed Imaging As 2',3'-dideoxyribofuranoxid-derivate.
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US5043339A (en) * 1988-12-19 1991-08-27 Burroughs Wellcome Co. Antiviral compounds
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
US5811538A (en) * 1993-12-30 1998-09-22 Genta, Incorporated Process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use

Also Published As

Publication number Publication date
CZ63397A3 (en) 1997-07-16
RO118748B1 (ro) 2003-10-30
NO971015L (no) 1997-03-05
ES2219666T3 (es) 2004-12-01
AU704977B2 (en) 1999-05-13
DE69533066T2 (de) 2005-06-02
PL188359B1 (pl) 2005-01-31
CA2199117C (en) 2006-04-11
SK28197A3 (en) 1997-09-10
US20050261320A1 (en) 2005-11-24
CA2199117A1 (en) 1996-03-14
FI970918A7 (fi) 1997-05-02
CN1827108A (zh) 2006-09-06
IS4434A (is) 1997-03-04
IL115156A (en) 2000-07-16
KR100374477B1 (ko) 2003-06-19
CN1111409C (zh) 2003-06-18
PL189288B1 (pl) 2005-07-29
HUT77172A (hu) 1998-03-02
FI970918A0 (fi) 1997-03-04
SI0781136T1 (en) 2004-08-31
CN1251680C (zh) 2006-04-19
DE69533066D1 (de) 2004-06-24
MY121548A (en) 2006-02-28
RU2168995C2 (ru) 2001-06-20
OA10473A (en) 2002-04-08
NO313268B1 (no) 2002-09-09
AU3586295A (en) 1996-03-27
US6063787A (en) 2000-05-16
IS2011B (is) 2005-05-13
IL115156A0 (en) 1995-12-31
KR970705393A (ko) 1997-10-09
EP0781136B1 (de) 2004-05-19
US20080171758A1 (en) 2008-07-17
EP1468687A1 (de) 2004-10-20
CN1448142A (zh) 2003-10-15
BG63122B1 (bg) 2001-04-30
NO971015D0 (no) 1997-03-05
EP0781136A4 (de) 1999-06-23
PT781136E (pt) 2004-09-30
AP9700939A0 (en) 1997-04-30
FI970918L (fi) 1997-05-02
NZ335013A (en) 2000-07-28
US7262213B2 (en) 2007-08-28
AP783A (en) 1999-11-17
SK284564B6 (sk) 2005-06-02
DK0781136T3 (da) 2004-08-02
US8076347B2 (en) 2011-12-13
CZ297873B6 (cs) 2007-04-18
CN1160351A (zh) 1997-09-24
EP0781136A1 (de) 1997-07-02
ZA957483B (en) 1997-06-06
WO1996007413A1 (en) 1996-03-14
BR9508886A (pt) 1997-12-30
JPH10506385A (ja) 1998-06-23
PL318971A1 (en) 1997-07-21
BG101284A (bg) 1998-03-31
JP3979662B2 (ja) 2007-09-19

Similar Documents

Publication Publication Date Title
DE69533066D1 (de) Verbindungen und verfahren zur behandlung von krebs
ATE230606T1 (de) Verfahren zur vorbeugung und behandlung von allergien
DE69425372D1 (de) Verfahren zur behandlung endo-ostealer materialien
DE69331469D1 (de) Verfahren zur behandlung von abfällen
EP1037625A4 (de) Verfahren zur herstellung von arsentrioxyd-formulierungen und verfahren zur behandlung von krebs mit arsentrioxyd oder melarsoprol
DE69730604D1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
ATE477270T1 (de) Verfahren und zusammensetzungen zur prävention und behandlung von anämie
DE69925266D1 (de) Verfahren und gerät zur behandlung von herzarhythmie
DE69112480D1 (de) Verfahren und Vorrichtung zur Behandlung von medizinischen Abfallstoffen.
DE69816070D1 (de) Verfahren zur Behandlung von Schredderstaub
DE69113681D1 (de) Verfahren und Vorrichtung zur Behandlung kontaminierter körniger Materialien.
DE69730097D1 (de) Verfahren und Vorrichtung zur Behandlung von Wafers
DE69829625D1 (de) Verfahren und Vorrichtung zur Behandlung von Perfluorokohlenstoff
DE69129194D1 (de) Vorrichtung und verfahren zur behandlung zellreicher suspensionen
DE69726289D1 (de) Verfahren und zusammensetzung zur behandlung von substraten bezüglich benetzbarkeit
ATE230617T1 (de) Verfahren und methode zur behandlung von abfällen
DE69714828D1 (de) Verfahren zur Behandlung von Abfallstoffen
DE69426485D1 (de) Verfahren und System zur Behandlung von verunreinigtem Wasser
DE69417018D1 (de) Verfahren zur behandlung von teilchenmaterial
DE69600480D1 (de) Verfahren und vorrichtung zur behandlung von aggregat
DE69518824D1 (de) Verfahren zur behandlung von bremsscheiben
DE69702997D1 (de) Verfahren zur Behandlung von verunreinigtem Aluminiumoxid
DE69328615D1 (de) Verfahren zur behandlung von viehhaltungsgülle
DE69607559D1 (de) Verfahren zur Behandlung von Phenolteer
DE69510990D1 (de) Verfahren und Vorrichtung zur Behandlung von metallichem Material

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0781136

Country of ref document: EP

REN Ceased due to non-payment of the annual fee